NPPB and pulmonary arterial hypertension: These preclinical studies predict that sGC stimulators can reduce pulmonary vascular resistance (PVR) and NT-proBNP as well as improve exercise tolerance in patients with PAH, providing the basis for regulatory approval of riociguat in patients with PAH.